Regenerex Pharma, Inc. - Form 8-K Filing Update

Regenerex Pharma, Inc. has filed a Form 8-K to update stakeholders on its SEC filing status. The company has completed and filed its 2025 Annual Report on Form 10-K, which was filed after the deadline. Regenerex Pharma is currently working to file its Quarterly Reports on Form 10-Q for the periods ending March 31, 2026, and June 30, 2026. These quarterly reports are currently delinquent, and the company acknowledges the failure to file notifications for late filing. The delays are attributed to significant additional accounting, reconciliation, and financial reporting work required following the 2025 Form 10-K. Management is actively working with advisors to complete these reports and become current with SEC obligations. The company is also strengthening its financial reporting processes to ensure future compliance. These delays are not expected to impact current operations or business strategy. Regenerex Pharma cautions that financial information for the delinquent periods should be considered incomplete until the reports are filed.